Heart failure is a leading cause of mortality and morbidity, and the search for novel therapeutic approaches continues. In the monogenic disease mucopolysaccharidosis VI, loss-of-function mutations in arylsulfatase B lead to myocardial accumulation of chondroitin sulfate (CS) glycosaminoglycans, manifesting as myriad cardiac symptoms. Here, we studied changes in myocardial CS in nonmucopolysaccharidosis failing hearts and assessed its generic role in pathological cardiac remodeling.
T
he failing heart undergoes extensive extracellular matrix (ECM) remodeling during disease progression. ECM contains structural components such as collagen and nonstructural components, including glycoproteins, proteoglycans, and glycosaminoglycans. 1, 2 Changes in ECM components are involved in important aspects of pathological cardiac remodeling such as the regulation of inflammation and fibrosis. [2] [3] [4] [5] Proteoglycans are composed of a protein core to which ≥1 glycosaminoglycan chains are attached. Glycosaminoglycans are unbranched polysaccharides including chondroitin sulfate (CS), dermatan sulfate (DS), heparan sulfate (HS), heparin, and hyaluronic acid (HA). CS/ DS and HS are highly sulfated and are therefore among the most negatively charged of all naturally occurring biomolecules with high molecular weight (MW). A group of rare diseases known as mucopolysaccharidosis I through VII exhibit systemic glycosaminoglycan accumulation caused by gene mutations in glycosaminoglycan degradation enzymes. Patients with mucopolysaccharidosis have progressive glycosaminoglycan deposition and multiorgan dysfunction, among which cardiac symptoms are common and early-onset. 6 Myocardial glycosaminoglycan accumulation manifests as ventricular fibrosis, hypertrophy, arrhythmia, valve leaflet disease, and in some cases ventricular aneurysm. 6, 7 Mucopolysaccharidosis VI is specifically caused by loss-of-function mutations in the gene encoding the arylsulfatase B (ASB) enzyme, leading to the accumulation of N-acetylgalactoseamine-4S, a component of the major CS subtype chondroitin-4-sulfate (C4S), and DS. Enzyme replacement therapy for patients with mucopolysaccharidosis VI with recombinant human ASB (rhASB) significantly reduces ventricular dysfunction in young patients, 8 and early treatment prevents abnormal cardiac development. 9 In individuals without mucopolysaccharidosis, aging and ischemic injury also result in myocardial proteoglycan and glycosaminoglycan accumulation. [10] [11] [12] [13] After ischemia/ reperfusion injury, CS accumulation inhibits sympathetic nerve reinnervation into the infarct area, leading to increased arrhythmogenicity.
14 Conversely, mice lacking the CS-rich proteoglycan (CSPG) receptor PTP-σ displayed reduced arrhythmia susceptibility. 15, 16 In the central nervous system, CS degradation in vivo mediated by the bacterial enzyme chondroitinase ABC [17] [18] [19] or rhASB 20 critically promoted postinjury functional recovery. We therefore hypothesized a role for CS in nonmucopolysaccharidosis pathological cardiac remodeling and tested the utility of CS targeting in heart failure treatment.
METHODS
The data, analytical methods, and study materials will be/ have been made available to other researchers for purposes of reproducing the results or replicating the procedure. Materials will be made available through direct contact with the authors of this article.
Human Left Ventricular Tissue
Human left ventricular (LV) tissue was collected with a protocol approved by the Papworth Hospital (Cambridge) Tissue Bank Review Board and the Cambridgeshire Research Ethics Committee (United Kingdom). Written consent was obtained from every individual according to the Papworth Tissue Bank protocol. LV explants were from white male patients undergoing cardiac transplantation for end-stage cardiomyopathy (EsCM). Normal LVs were from healthy white age-matched male individuals (United Kingdom Human Tissue Bank, de Montfort University). At the time of transplantation or donor harvest, whole hearts were removed after preservation and transported as previously described. 21 Individual sample details are listed in Table I in the online-only Data Supplement.
Human and Mouse Primary Cell Culture and In Vitro Treatment
Human primary cardiac fibroblasts (CFs) and coronary artery endothelial cells (ECs) were purchased from PromoCell; coronary artery smooth muscle cells (SMCs) were purchased from Thermo Scientific (donor information is listed in Table II 
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Circulation. ORIGINAL RESEARCH ARTICLE primary cardiomyocytes and CFs were isolated as described previously. 22 Hypoxia treatment was performed by subjecting cells to 0.2% oxygen for 2 or 24 hours. Oxidative stress was applied by adding tert-butyl hydroperoxide (TBH) 50 µmol/L (TBH 50) or 200 µmol/L (TBH 200) into the human cardiac cell culture media for 4 hours. The TBH concentration used in mouse cardiomyocytes was 1 and 5 µmol/L instead to account for higher sensitivity to toxicity. Cytokines, including interleukin (IL)-1β, transforming growth factor-β (TGFβ), tumor necrosis factor-α (TNFα; Peprotech), and angiotensin II (Sigma), were added to the cell culture media at 10 ng/mL each for 4 hours. The combined "HIT" treatment involved first subjecting cells to 24 hours of hypoxia, followed by adding IL-1β and TGFβ into culture media at 10 ng/mL each during the last 4 hours.
For TNFα treatment experiments, CS-A was coated onto plastic substrate by incubating cell culture wells with 50 µg/ mL CS-A solution for 2 hours at 37°C. rhASB-pretreated CS-A was prepared by adding 50 µg/mL CS-A and 50 µg/mL rhASB to Ca 2+ plus PBS and incubating in wells for 2 hours at 37°C. Excess incubating solution was removed by washing after 2 hours. TNFα recombinant protein was then added to the wells and incubated for a further 20 minutes at 37°C. Unbound TNFα was removed by washing with PBS thereafter. ECs or macrophages were finally seeded onto the substrate and cultured for 6 hours. Cells were harvested in TriReagent (Qiagen) for RNA extraction.
In Vivo Procedures
All animal procedures were performed according to a protocol approved by the National University of Singapore Institutional Animal Care and Use Committee. The main experimenters were blinded to animal grouping until data collection was finalized.
Pressure overload was performed by applying an incompletely closed vessel occlusion clip (Weck Haemoclip) around the aorta between the branches of the brachiocephalic artery and the left carotid artery. 23 A fixed width of the occlusion clip was achieved by adjusting the closure to the width of a 0.5-mm metal wire. Transverse aortic Doppler ultrasound examination was performed for each rat to verify equal pressure gradients across the occlusion clip stenosis. Fifteen adult animals received sham surgery, and 25 received transverse aortic constriction (TAC) surgery. Four animals that received TAC surgery died within the first 24 hours of surgery and were excluded from subsequent study analysis. Groups were assigned in random order. rhASB (BioMarin, Naglazyme, 1 mg/mL) or saline was injected at 1 mL/kg body weight intravenously through the tail vein each week, and echocardiography was performed weekly. Rats were euthanized 10 weeks after TAC or sham surgery. For sham surgery, rats underwent thoracotomy, but the occlusion clip was not applied. rhASB administration route, frequency, and dosage were used as in clinical practice. 24 Sample sizes in each group were as follows: sham+saline (S+S), n=12; sham+rhASB (S+A), n=3; TAC+saline (T+S), n=12; and TAC+rhASB (T+A), n= 9. To study the temporal profile of C4S accumulation, TAC surgery was performed in 6 additional rats. These hearts were harvested on weeks 1, 2, and 4 after TAC (n=2 per group).
For the isoprenaline model, isoprenaline (MedChem Express) was administered by osmotic minipump (2ML2, Alzet) over 4 weeks. Isoprenaline was diluted to 20 mg/mL in saline, and rats received on average 3 mg/kg body weight per day. By week 5, animals whose ejection fraction (EF) was still >70% (n=6) were excluded from subsequent procedures. Control animals received sham surgery without pump implantation. Animals were randomized at week 5 to receive either rhASB (BioMarin, Naglazyme, 1 mg/mL) or saline at 1 mL/kg body weight via the tail vein each week. Echocardiography was performed at fixed time points. Animals were euthanized 9 weeks after the start of isoprenaline treatment. Sample size in each group was as follows: S+S, n=8; S+A, n=7; isoprenaline+saline, n=9; and isoprenaline+rhASB, n=9.
Statistical Analysis
Statistical analysis was performed in Graphpad Prism (GraphPad Software, Inc) with 1-way ANOVA (for comparison between 4 groups) or Student t test (for comparison between 2 groups). Results are shown as mean±SEM, with the specific tests used in each of the figures and tables provided in their corresponding legends. The sample sizes for animals, cells, and tissue samples in each group are also displayed in the legends of figures and tables.
The online-only Data Supplement provides further methods on liquid chromatography-mass spectrometry (LCMS), CS quantification assay, quantitative reverse transcription-polymerase chain reaction (Tables III and IV 
RESULTS

CS Accumulation in Failing Human Hearts
First, we performed CS immunostaining with the monoclonal antibody 2H6, which probes for the major CS component of C4S, N-acetylgalactosamine-4-sulfate ( Figure 1A and Figure I in the online-only Data Supplement). LV sections were from patients with nonmucopolysaccharidosis heart failure with EsCM and age-, sex-, and race-matched healthy control subjects (n=6 each; sample details given in Table I in the online-only Data Supplement). In EsCM LV samples, there was consistent and significant perivascular and interstitial CS accumulation, particularly in regions of intense fibrosis ( Figure 1A and Figure I in the online-only Data Supplement). We further quantified total glycosaminoglycan content in extracted glycosaminoglycans and CS using an Alcian blue assay. Total glycosaminoglycan in EsCM samples was 3 times more abundant than in healthy controls (3.43±1.33 versus 1.02±0.37 µg/mg dry weight of lyophilized heart tissue; P=0.003; Figure 1B) . In particular, CS was 3-fold more abundant in EsCM (2.23±1.06 versus 0.71±0.29 µg/mg; P=0.009). We proceeded to subanalyze CS disaccharide relative composition by LCMS. Similar to the CS composition in other organs, 25 C4S was indeed the main CS component in human LV ( Figure 1C ). Relative CS composi-
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tion remained unchanged between control and EsCM LV samples ( Figure 1C ).
Cell-Specific Analysis for CSPG Regulation
To gain a clearer insight into CS deregulation in the failing heart, we asked which myocardial cell types were responsible for CSPG accumulation and which stimulants triggered the change. Because glycosaminoglycan synthesis, unlike nucleic acids or proteins, is not template-driven but is instead dynamically modulated by a series of processing enzymes, 26 we profiled for the mRNA expression of genes encoding for glycosaminoglycan-processing enzymes as an indication of overall glycosaminoglycan synthesis and processing in the different cell types of the heart (Figure 2 ). This included mRNA expression of CSPG protein cores, glycosaminoglycan chain initiation and elongation enzymes, CS sulfatases, and CS degradation enzymes. In addition, because a large proportion of CSPGs are known to bind to HA, 27 we profiled for HA synthases ( Table III in the online-only Data Supplement gives the full gene list). We quantified the expression of these mRNAs in a panel of human primary myocardial cell types, including CFs, SMCs, and ECs. Because macrophage infiltration may be relevant to CSPG biology in the myocardium, we also included the monocyte cell line THP-1 and macrophages differentiated from THP-1 cells with phorbol myristate acetate treatment. Notably, all 4 cell types were positive for C4S by immunostaining ( Figure 3A ). Cell identity was validated by morphology ( Figure 3A ) and expression of their respective cell type-specific markers ( Figure IIA in the online-only Data Supplement). Each cell type was subjected to 9 different culture conditions ( Figure 2 ). Related to the expression of the CSPG protein-core, we found that the large HA-binding versican gene (VCAN) was highly expressed in CFs and SMCs, the small leucinerich proteoglycans decorin (DCN) and lumican (LUM) genes were expressed in CFs, and biglycan (BGN) expression was detected in CFs, SMCs, and ECs. Low expression of the cell surface CSPG CD44 in monocytes and macrophages was upregulated after exposure to oxidative stress Expression of genes related to (A) CSPG protein cores, (B) enzymes for glycosaminoglycan (GAG) chain initiation and CS chain elongation, (C) chondroitin-4-sulfate/D4S sulfotransferases, (D) enzymes involved in CS/dermatan sulfate degradation, and (E) hyaluronic acid synthases. Each cell type was exposed to 9 culture conditions, represented by the color-coded background. Data represent relative expression of each gene normalized to 10 000th of 18S rRNA expression, presented as mean±SD. n=3 for each culture condition. Ang-II indicates angiotensin II; CF, cardiac fibroblast; Ctrl, control; EC, endothelial cell; IL-1β, interleukin-1β; SMC, smooth muscle cell; TBH, tert-butyl hydroperoxide; TGFβ, transforming growth factor-β; and TNFα, tumor necrosis factor-α. *Undifferentiated THP-1 cells. (TBH) and by IL-1β. DCN, but not VCAN, was upregulated in CF by 24 hours of hypoxia, whereas expression of all other protein-core genes was not altered by stimulation (Figure 2A ). Related to CS chain synthesis, the gene for the glycosaminoglycan chain initiation enzyme xyloside transferase 1 (XYLT1) was highly upregulated by TGFβ in CFs and SMCs. The CS chain elongation enzyme CHPF was highly expressed in CFs and SMCs, and CHSY1 was preferentially expressed in macrophages. CHPF was upregulated in CFs by hypoxia and TBH-induced oxidative stress. CHSY1 was upregulated in macrophages by all treatment conditions ( Figure 2B) . A further step in glycosaminoglycan synthesis is CS sulfation. The C4S sulfotransferase gene C4ST1 was expressed in macrophages and further significantly upregulated in CFs by IL-1β, TNFα, and TGFβ.
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In the other cell types, the main sulfotransferase expressed was the D4S sulfotransferase D4ST1 ( Figure 2C ). In the pathways leading to CS degradation, ARSB was expressed more in SMCs than in other cell types. However, mRNA abundance for all glycosaminoglycan degradation enzymes was notably unaltered by any condition ( Figure 2D ). Western blot also showed no significant change in ASB protein induced by any treatment condition ( Figure 3E ), reflecting the overall likelihood that myocardial cell types do not effectively upregulate CS degradation to counterbalance the increased expression of genes related to CS synthesis. Despite being known as a lysosomal enzyme, the ASB enzyme was found to be abundant in CF-conditioned media in addition to cell pellet lysates ( Figure 3E ), suggesting that at least in this context, ASB is secreted by CFs in significant quantities.
CSPG production in cardiomyocytes was measured in cardiomyocytes and CFs freshly isolated from mouse hearts because of the unavailability of primary human cardiomyocytes. Gene expression of proteoglycan core proteins and C4ST1 under similar culture conditions as described above was measured with quantitative reverse transcription-polymerase chain reaction ( Figure  IIB and IIC in the online-only Data Supplement). Compared with mouse CFs, CSPG production was virtually absent in mouse cardiomyocytes. Cell viability and the mouse cardiomyocyte stress response were confirmed by expression levels changes in Nppb.
Because CFs convincingly integrated mRNA increases responsible for CSPG protein core synthesis (eg, DCN), CS chain elongation (eg, CHSY1 and CHPF), and CS sulfation (C4ST1), and because we had found significant CS accumulation in areas of myocardial fibrosis in our failing hearts, we chose CFs to pursue a more detailed investigation into stress-induced CSPG upregulation. Consistent with the findings above, TGFβ upregulated the gene expression of CS chain initiation and elongation enzymes, and IL-1β upregulated the expression of C4S sulfotransferase in CFs ( Figure 3B) . A C4S dot blot using conditioned media collected from CFs treated with hypoxia, IL-1β, or TGFβ alone and the combination of all 3 (HIT treatment) confirmed that TGFβ induced a C4S increase, further augmented by the HIT combination treatment ( Figure 3C ). We further investigated whether these treatment conditions also induced CS chain extension by using DCN as a CSPG representative. DCN is a small CSPG with 1 glycosaminoglycan chain of either CS or DS. Glycosaminoglycan chain length can thus be deduced by comparing the difference in MW between the complete CSPG (ie, DCN with glycosaminoglycan chain) and its protein core alone (DCN without CS chain). Empirically, the protein core can be obtained by treating CSPGs with chondroitinase ABC, a potent bacterial enzyme that digests all CS/DS glycosaminoglycan chains into disaccharides. We noted that the abundance of the DCN protein core was increased by hypoxia, TGFβ, and combined HIT conditions (DCN without CS chain in Figure 3D ). Concurrently, the MW of complete DCN was increased from 75 to ≈100 kDa by the combined HIT treatment (DCN with CS chain in Figure 3D ). Because the MW of the DCN core protein is not expected to change, the MW increase of complete DCN may be attributed to increased CS chain extension, implying that at least for the example of DCN, treatment conditions upregulated CSPG abundance and CS chain length extension.
High-MW Molecules Secreted by CFs Activated IL-1β Upregulation in Macrophages
Next, we noted that HIT treatment in CFs also induced a 2-fold increase in secreted proteins ( Figure 3F ). We collected the conditioned media and filtered and concentrated Figure 3 Continued. blot for arylsulfatase B (ASB) in CF-conditioned media and in CF cell pellet lysate. GAPDH was used as loading control for cell pellet lysates. F, Protein concentration of conditioned media collected from HIT-treated CF was significantly increased. G, CFs secreted high-MW extracellular matrix proteins after HIT treatment that induced IL1B upregulation in macrophages. CFs were treated with HIT conditions, and the conditioned media was filtered with a 50-kDa cutoff membrane. The high-MW portion (free of cytokines) was added to in vitro cultured macrophages. IL1B expression was significantly upregulated in macrophages (***P<0.001, right pair of data). Direct incubation with IL-1β and TGFβ into media also induced significant IL1B upregulation in macrophages (***P<0.001, left pair of data). Cell-free media treated with the same HIT conditions and filtered with 50-kDa cutoff membrane did not trigger IL1B changes when added to macrophage culture (middle pair of data). H, TNFA expression in macrophages as in G. Unlike IL1B, CF-conditioned media did not induce TNFA upregulation, whereas IL-1β and TGFβ cytokines significantly induced upregulation. n=3 for each experiment. Conc. indicates concentration; Ctrl, control; TBH, tert-butyl hydroperoxide; w/, with; and w/o, without.
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it with a 50-kDa MW cutoff membrane. Cytokines with low MW (<20 kDa) were filtered away, leaving behind only high-MW secreted proteins. When added to a macrophage culture, CF-secreted high-MW proteins induced IL1B, but not TNFA, gene upregulation in macrophages differentiated from THP-1 cells ( Figure 3G and 3H) . The level of IL1B gene upregulation was comparable to that of direct macrophage stimulation with IL-1β and TGFβ at 10 nmol/L per 1 mL, suggesting that under pathological conditions, CFs secreted large extracellular molecules with inflammatory properties, capable of activating immune cells through specific pathways. Although this conditioned medium is expected to contain myriad large extracellular molecules, many of which could possess proinflammatory properties, we have verified that HIT treatment induced a dramatic increase in secreted CSPGs containing C4S ( Figure 3C ).
CS Accumulation in a Rat Model of Pressure-Overload Cardiac Remodeling
Among rodents, rats rather than mice are similar to humans in terms of CS production. 28 To test the generality of CS accumulation as a process of pathological remodeling in cardiomyopathy in vivo, we therefore analyzed myocardial CS changes in 2 rat models of pathological remodeling. First, we surgically induced pressure overload by TAC using the clip-TAC technique 23 ( Figure 4A ). The degree of stenosis was controlled by a mechanical stopping device to ensure consistency ( Figure IIIA and IIIB in the online-only Data Supplement). In this model, myocardial hypertrophy was accompanied by significant accumulation of C4S ( Figure 4B ), similar to our findings in human hearts. C4S deposition was observed as early as 1 week after TAC, persisted throughout the course of observation, and colocalized to fibrotic regions as visualized by concurrent Sirius red staining ( Figure IIIC in the online-only Data Supplement). As in diseased human myocardium, C4S was also observed to accumulate in the perivascular space and the myocardial interstitium ( Figure IIIC in the online-only Data Supplement and Figure 4B ). Additional staining for polysaccharides was performed with Alcian blue at pH 0.5, which stains only sulfomucins, or with colloidal iron, which stains total mucin. In the TAC heart, both staining patterns repli- ORIGINAL RESEARCH ARTICLE cated that of the 2H6 antibody for C4S and colocalized well with regions of fibrosis ( Figure 4C ). Taken together, this provided good evidence that the sulfomucin CS is accumulated in fibrotic regions of the pathologically remodeled LV.
Systemic rhASB Treatment in TAC Rats Reduced Myocardial CS Content
Complete CS degradation and turnover require the removal of sulfate groups from sulfated disaccharides as part of the prerequisite sequential steps. 28 ASB is the sulfatase specific for C4S. Because C4S is the predominant component of myocardial CS in pathological remodeling (≈80% of total CS; Figure 1C ) and we had noted that under disease stimulus, cardiac cell types did not efficiently upregulate ASB abundance ( Figure 3E ), we proceeded to treat TAC-operated rats with rhASB to investigate its effect on cardiac CS and overall cardiac function (study design in Figure 4A ).
Immunofluorescence staining for C4S confirmed that rhASB treatment resulted in significant CS reduction ( Figure 4C ). We extracted and quantified CS from rat heart tissue by the end of rhASB treatment. Quantified with the Alcian blue assay, total CS abundance was increased by TAC (P<0.001) and significantly reduced by rhASB (P=0.022; Figure 4D ). Relative CS disaccharide composition measured by LCMS showed a trend toward increased C0S proportion in the 2 rhASBtreated groups ( Figure 4E ), whereas the disaccharide composition of another glycosaminoglycan group, HS, remained unchanged ( Figure 4F ).
rhASB Treatment Alleviated Fibrosis, Inhibited Inflammation, and Attenuated Cardiac Deterioration
Rats were divided into 4 groups to receive either sham surgery and saline or rhASB treatment (S+S and S+A) or TAC surgery and saline or rhASB treatment (T+S and T+A). TAC surgery induced significant hypertrophy and a decrease in EF compared with the sham-operated groups ( Figure 5A and 5B). RhASB treatment, initiated 2 weeks after TAC, maintained EF during the treatment course of 8 weeks after TAC (P<0.001; Figure 5B ). Posterior wall thickening, which measures the percentage change of posterior wall thickness between diastole and systole, and stroke volume showed sustained healthy myocardial function in the rhASBtreated group ( Figure 5C -5E) compared with saline treatment. Hypertrophy measured by histology, echocardiography, and heart weight/body weight ratio did not show significant changes in this experiment ( Figure IIID -IIIG in the online-only Data Supplement), possibly because of the constant presence of the surgical aortic constriction. Instead, myocardial fibrosis was significantly decreased by rhASB treatment compared with TAC and saline treatment (8.9±0.67% and 5.9±0.92% in the T+S and T+A groups, respectively; P<0.001; Figure 5F and 5G).
Next, we searched for an underlying mechanism to explain the positive effects of rhASB. Fibrosis and immune responses in the cardiac ECM are closely linked processes, and we had found above that CF-secreted CSPGs may modify immune responses. We therefore quantified the immune reaction in our rat LV by counting the number of macrophages ( Figure 5H and 5I Figure IVC and IVD in the online-only Data Supplement).
rhASB Rescued Cardiac Function in the Isoprenaline Infusion Model of Pathological Remodeling
In the next in vivo experiment, we tested the effect of delayed rhASB treatment in rats implanted with subcutaneous osmotic pumps releasing isoprenaline at an average rate of 3 mg/kg body weight for 4 weeks. Isoprenaline induces cardiomyocyte necrosis through activating the β-adrenergic pathway. 29 Two weeks after the start of the isoprenaline infusion, we observed regions of severe ischemic injury colocalized with abundant CD45 + leukocyte infiltrate ( Figure VA and VB in the online-only Data Supplement). By week 5, the EF in the isoprenaline-treated rats was reduced to 62.55±6.4%. Five weekly rhASB injections were initiated from week 5 after isoprenaline infusion ( Figure 6A) .
First, we compared the CS and HS distribution patterns again in the rat heart sections after 2 weeks of isoprenaline treatment. Overall polysaccharide staining with colloidal iron and acidic sulfated polysaccha-
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ride with Alcian blue at pH 0.5 indicated enrichment of polysaccharides, especially acidic sulfated polysaccharides, in the fibrotic regions. Specific immunostaining with monoclonal antibodies for CS (CS56), C4S (2H6), and HS (10E4) revealed that CS, especially C4S, was highly enriched in the fibrotic regions (Figure 6B and 6C ), whereas HS distribution was more homogeneous ( Figure VC and VD in the online-only Data Supplement). This effectively recapitulates the consistent pattern of C4S, but not HS, accumulation again in fibrotic regions of pathological cardiac remodeling. By week 9, we observed a reduction of fibrosis in rhASB-treated animals compared with saline-treated animals, accompanied by a decreased level of sulfated polysaccharides (observed by Alcian blue staining at pH 0.5) and C4S content (2H6; Figure 6B ). Myocardial fibrosis was again significantly lower with rhASB treatment (Sirius red staining; 3.2±0.56%, 3.0±0.85%, 9.9±2.67%, and 6.61±1.66% fibrotic area in the S+S, S+A, isoprenaline+saline, isoprenaline+rhAS groups, respectively; Figure 6D ). Echocardiography displayed a significantly accelerated recovery of contractile functional in the rhASB-treated group (Figure 7A-7C) . Remarkably, some rhASB-treated animals recovered to the normal functional range as assessed by their EF (Figure 7D ). Similar recovery was seen with posterior wall thickening and stroke volume (Figure 7E and 7F ).
TNFα Bound Directly to CS Glycosaminoglycans and Mediated Downstream Gene Expression Responses
CSPGs are known triggers of inflammation by activating Toll-like receptors.
30-34 Hence, we investigated whether myocardial CS, like other glycosaminoglycans, mediated its effect by presenting specific extracellular ligands to cell surfaces, thereby activating cellular downstream signaling. We first assayed for the disaccharide composition of commercial biotinylated CS products by LCMS and found that the CS-A product has a composition similar to that of human and rat heart CS ( Figure 8A ). Then, to identify ligands of CS in myocardial ECM, we 
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undertook a candidate approach and performed CSprotein interaction assays using the Surface Plasmon Resonance system. Biotinylated CS, CS-A, heparin, or BSA was prebound to the ProteOn NeutrAvidin-coated NLC sensor chip, and the affinity between glycosaminoglycans and candidate proteins was measured. Heparin was used as a positive control because it has the highest negative charge of all glycosaminoglycans and hence was expected to display the strongest protein-binding affinity ( Figure 8B ). BSA was used as the reference to which each interaction was normalized. As anticipated, CS had a very low binding affinity to human serum albumin, fibrinogen, and immunoglobulin G (Figure 8B ), corresponding to its overall antiprotein adhesion function. Among the candidate cytokines, TNFα, but not TGFβ or IL-6, bound strongly to CS-A, suggesting a unique and specific affinity between TNFα and CS-A. In particular, the interaction between CS-A and TNFα was not dissociated by high-salt buffer or detergent washing.
Last, we undertook in vitro experiments to assess the direct effect of CS-A and TNFα binding. Cell culture plates were precoated with poly-d-lysine, CS-A, or CS-A and rhASB and subsequently preincubated with TNFα before washing of the plates and seeding of the primary human CFs. Expression of the TNFα target gene VCAM1 was assessed. TNFα bound to CS-A, but not poly-d-lysine, and effectively upregulated VCAM1 expression ( Figure 8C ), confirming that A, M-mode echocardiographic images of rat hearts at week 9. I+A indicates isoprenaline+rhASB (n=9); I+S, isoprenaline+saline (n=9); S+A, sham+rhASB (n=7); and S+S, sham+saline (n=8). B, Representative M-mode echocardiography from rats in group I+A at 3 time points during the treatment period. C, Ejection fraction (%EF) measured over time. ***P<0.001 (2-way ANOVA for repeated measures followed by Tukey post hoc test). D, %EF measured at week 9. *P=0.039 (1-way ANOVA followed by Tukey post hoc test; data represented as individual values and mean±SD; same statistical method applies to E through G). E, Percentage posterior wall thickening (%PWT), percentage change of wall thickness between diastole and systole, at week 9. **P=0.0065. F, Stroke volume (SV) at week 9. ***P<0.001. BL indicates baseline.
the binding effect of CS-A indeed supports TNFα signaling activation, rather than sequestering or decoying TNFα. The same effect was also observed when the experiment was performed on macrophages differentiated from THP-1 cells. Macrophage activation was measured by quantitative polymerase chain reaction of the TNFA gene ( Figure 8D ). Remarkably, TNFA signal activation was completely abolished when cells were cultured on CS-A that was pretreated with rhASB, reflecting the potent negative effect of rhASB on CS-A-mediated TNFα downstream signaling. 
DISCUSSION
Proteoglycan complexes are widely synthesized in connective tissue, platelets, and blood vessels. 35 In cardiac disease, HSPGs and HA have been extensively studied in the context of vascular disease and myocardial fibrosis, immune cell recruitment, ECM remodeling, and cardiac dysfunction. [36] [37] [38] [39] [40] [41] [42] [43] On the other hand, much less is known about the role of CSPGs and CS glycosaminoglycans in cardiac remodeling. CSPGs are molecules consisting of protein cores and CS glycosaminoglycan chains. Differentially attached CS chains may modify the functional behavior of CSPGs. 30, 32, 33 In this study, we have comprehensively investigated the composition, synthesis, regulation, and mechanistic interactions of myocardial CS and uncovered its remarkable potential for targeting cardiac fibrosis in pathological remodeling.
Although patients with other forms of mucopolysaccharidosis also show multiorgan glycosaminoglycan accumulation, including in the myocardium, our discovery of the predominant C4S component in nonmucopolysaccharidosis failing hearts led us to focus on the more generic relevance of mucopolysaccharidosis VI. Patients with the monogenic disease mucopolysaccharidosis VI harbor loss-of-function mutations in the ARSB gene and indeed manifest a range of systemic conditions, including heart failure, reflecting the importance of CS regulation in maintaining normal cardiac function. Characterization of total myocardial CS by LCMS revealed that the relative disaccharide composition remained constant between health and disease, and C4S was the predominant CS component. This observation was replicated in 2 rat models of pathological cardiac remodeling.
In vitro screening for CSPG-related genes showed that different cardiac cell types used different enzymes for differential CS synthesis. Macrophages exclusively expressed the C4S sulfotransferase C4ST1, whereas the D4S sulfotransferase D4ST1 was highly expressed in other cell types. C4S and D4S are stereoisomers. This raises the possibility that the CS/DS molecular chirality plays a role in mediating their molecular interactions in the myocardium. Nonetheless, for CSPG regulation, we found that TGFβ was sufficient to induce CS upregulation and that the combination of hypoxia, IL-1β, and TGFβ (HIT) upregulated not only CSPG abundance but also CS chain extension, as represented by the increase in overall DCN MW. Because in vivo pathophysiology involves the combined effect of hypoxia and cytokines, this result is consistent with the notion that CSPGs are indeed upregulated both in abundance and in chain length in diseased hearts.
In human primary CF culture, we found that ASB is abundantly secreted into the media, despite being classically known as a lysosomal enzyme. Weekly infusion of rhASB is the US Food and Drug Administration-approved treatment for patients with mucopolysaccharidosis VI, targeted to reduce systemic glycosaminoglycan accumulation. 6, 24, 44 In a rodent model of spinal cord injury, rhASB effectively eliminated CS with a single injection into spinal cord tissue, leading to increased axon regeneration and improved motor function. 20 In human ECs, rhASB negatively regulated CSPG versican expression and reduced versican-attached C4S. 45 ASB repression reproduced the effect of hypoxia with increased C4S content, whereas ASB overexpression reduced the nuclear hypoxia-inducible factor level. 46 In this study, we observed that systemic rhASB treatment effectively reduced total myocardial CS content in the rat models of heart failure. Early rhASB treatment prevented TAC-induced functional deterioration in the TAC model without affecting cardiac hypertrophy. In human patients with mucopolysaccharidosis VI, rhASB significantly improved hypertrophy in patients younger, but not those older, than 12 years. This reason for this difference may be that in older patients, chronic glycosaminoglycan deposition had caused irreversible aortic valve deformation resulting in fixed aortic stenosis. Hypertrophy was therefore unchanged in the presence of the fixed unaltered pressure gradient. 8 In our TAC model, the lack of hypertrophic improvement may also be explained in a similar way because the TAC pressure gradient was not removed. Nonetheless, cardiac functional improvement, despite unchanged hypertrophy, suggests that fibrosis reduction resulted from an inhibition of pathological processes that also influence contractility. We speculate that this is likely caused by positive myocardial remodeling itself because the ECM, including inflammatory infiltrates, was significantly different in ASB-treated animals. To circumvent the issue of sustained pressure gradient in the TAC model, we turned to the isoprenaline-infusion model to test for fibrosis rescue. Here, after the onset of pathology with isoprenaline infusion, we were still able to find improved fibrosis and functional rescue from delayed rhASB treatment, consistent indeed with a property of fibrosis rescue.
As a large class of glycosaminoglycan molecules, CSPGs are made up of multiple forms with many overlapping functions, including small collagen binding proteins with inflammatory properties (eg, the small leucine-rich proteoglycans DCN and biglycan), large HA-binding ECM proteins (eg, versican), and membrane proteins (eg, CD44). The effect of CSPG modifications in the heart is therefore likely to be complex and multifaceted and probably involves multiple cell types, including immune cells, vascular cells, cardiac nerves, and others. Here, we focused our investigation on 1 potential mode of action. Fibrosis and chronic inflammation in the heart are known to perturb contractile function, [47] [48] [49] [50] [51] [52] and inflammatory processes are major mediators of cardiac fibrosis. [53] [54] [55] [56] [57] In rats, rhASB treatment led to reduced numbers of CD45-positive immune cells, as well as CD68-and Iba1-positive macrophages, supporting a functional role for CS in aggravating the myocardial inflammatory cell response during pathological remodeling. CSPGs are mediators of both innate and adaptive immune responses. 58 Although under normal conditions, CSPGs are membrane-or ECM-bound and do not trigger an immune reaction, soluble CSPGs derived from proteolytic digestion of ECM or CSPGs newly synthesized by macrophages are recognized as potent danger signals. 59 The CSPGs versican and DCN activate macrophages and other myeloid cells to secrete proinflammatory cytokines through binding to Toll-like receptors, CD44, and mannose receptors. 32, [60] [61] [62] The glycosaminoglycan component is indispensable for the interaction with cell surface receptors and consequent immune cell activation. 31, 59, 63 Our work now sheds light on how CSPG accumulation in pathological cardiac remodeling integrates signals contributing to the inflammation and fibrotic processes. Furthermore, we identified TNFα as a direct binding partner to CS glycosaminoglycan chains. Notably, the binding to TNFα did not require the presence of the proteoglycan protein core. TNFα bound to CS-A triggered upregulation of genes in the TNFα pathway in ECs and macrophages, which was, in turn, significantly inhibited by rhASB. This is consistent with the model that CS-A glycosaminoglycans present TNFα to cells, rather than sequester or decoy the molecule, and that the in vivo rhASB effect is at least partly caused by the interference of the TNFα pathway. Remarkably, this finding is also consistent with data from early clinical studies in which an increased TNFα mRNA level was observed in patients with mucopolysaccharidosis VI compared with healthy control subjects and was reduced by 5-fold after 1 month of rhASB treatment. 64, 65 Together, these lines of evidence suggest that CSPGs induce inflammation through an interaction between the CS glycosaminoglycan chain and TNFα, in addition to direct activation of immune cells through their cell surface receptors.
Finally, the CSPGs DCN and biglycan belong to the category of small leucine-rich proteoglycans that bind to collagen and facilitate collagen fibril formation and fiber alignment. 66, 67 DCN and biglycan double-deficient mice displayed reduced collagen synthesis. 68 It is conceivable that interfering with collagen-binding CSPGs also affects collagen fiber formation or stability, thereby reducing collagen synthesis or increasing collagen turnover. Further studies are necessary to investigate whether collagen organization and stability are altered by rhASB treatment.
Taken together, our results indicate for the first time that myocardial CSPG accumulation is maladaptive and triggers inflammatory and profibrotic processes in pathological cardiac remodeling. Glycosaminoglycan regulation is delicately controlled by environmental cues through the regulation of a battery of glycosaminoglycan synthesis and degradation enzymes and played out by the different important myocardial cell types. Targeting CS accumulation such as with rhASB represents a novel therapeutic approach for pathological cardiac remodeling in heart failure.
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